Effects of ticagrelor and aspirin on coagulation function and platelet aggregation in patients with coronary heart disease undergoing interventional therapy

Abstract

Objective To investigate the effects of ticagrelor and aspirin on the coagulation function and platelet aggregation in patients with coronary heart disease (CHD). Methods A total of 90 patients with CHD treated by interventional therapy in Linfen People’s Hospital from November 2015 to December 2018 were selected as the study subjects. All patients were divided into study group and control group by random number table method, with 45 cases in each group. Two groups of patients with CHD were treated by percutaneous coronary intervention (PCI). The study group received aspirin and ticagrelor on the basis of conventional treatment after PCI. The control group received aspirin and chlorine on the basis of conventional treatment after PCI. The coagulation function, platelet aggregation rate and drug safety were compared between the two groups. Results Before treatment, there were no significant differences in activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen (Fbg), thrombin time (TT), platelet aggregation rate (Pagt) between the two groups (P>0.05). After treatment, APTT, PT, TT, Pagt in the study group were better than those in the control group(P>0.05). After treatment, Fbg levels in the control group were higher than those before treatment (P 0.05). There was no significant difference in the occurrence of adverse reactions between the study group and the control group (P>0.05). Conclusions The clinical efficacy and safety of aspirin and ticagrelor in patients with CHD after PCI are better, which can significantly improve their coagulation function and platelet aggregation status. Key words: Coronary heart disease; Interventional therapy; Ticagrelor; Coagulation; Platelet aggregation